scholarly journals Management of Peritonsillar Abscesses in Adults: Survey of Otolaryngologists in Canada and the United States

OTO Open ◽  
2021 ◽  
Vol 5 (3) ◽  
pp. 2473974X2110440
Author(s):  
David Forner ◽  
Christopher W. Noel ◽  
Amy Grant ◽  
Paul Hong ◽  
Martin Corsten ◽  
...  

Objective The management of peritonsillar abscess (PTA) has evolved over time. We sought to define contemporary practice patterns for the diagnosis and treatment of PTA. Study Design Cross-sectional survey. Setting The 15-question survey was distributed to members of the Canadian Society of Otolaryngology–Head and Neck Surgery (CSO) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS). Methods An iterative, consensus-based process was used for survey development. Primary outcomes were to determine methods of diagnosis and first-line treatments for PTA. Exploratory, secondary outcomes were analyzed using multivariable logistic regression models. Results The survey response rate was 12.6% (n = 1176). Most participants were attending staff (86%) in a community hospital setting (60%) and had been in practice for more than 20 years (38%). Most respondents (78%) indicated that at least half of the time, cross-sectional imaging had already been performed before they were consulted. Half of respondents (49%) indicated that they perform incision and drainage of the abscess as first-line treatment, while few (16%) provide medical management alone. In exploratory analysis, participants from the AAO-HNS had higher odds of imaging already being performed before consultation (odds ratio [OR], 11.7; 95% CI, 4.6-29.4) and increased odds of using medical management alone as a first-line treatment (OR, 2.4; 95% CI, 1.3-4.2) compared to respondents from the CSO. Conclusion There is wide practice variation in the diagnosis and management of acute, uncomplicated PTA among otolaryngologists in Canada and the United States. The use of cross-sectional imaging and medical management alone may differ between countries of practice.

2016 ◽  
Vol 14 (5) ◽  
pp. e479-e487 ◽  
Author(s):  
Michelle D. Hackshaw ◽  
Michael Holmes ◽  
Maria Lankford ◽  
Michele Thomas ◽  
Augustina Ogbonnaya ◽  
...  

2015 ◽  
Vol 18 (10) ◽  
pp. 763-776 ◽  
Author(s):  
Siyang Peng ◽  
Ali Tafazzoli ◽  
Emily Dorman ◽  
Lisa Rosenblatt ◽  
Angelina Villasis-Keever ◽  
...  

2015 ◽  
Vol 19 (4) ◽  
pp. 352-357 ◽  
Author(s):  
Aditya K. Gupta ◽  
Danika C.A. Lyons

Background: Ketoconazole was the first broad-spectrum oral antifungal agent available to treat systemic and superficial mycoses. Evidence of hepatotoxicity associated with its use emerged within the first few years of its approval. Growing evidence of serious side effects including endocrine dysregulation, several drug interactions, and death led to the review of oral ketoconazole in 2011. Objective: This article chronicles the use of oral ketoconazole from its introduction to its near replacement in medicine. Conclusion: Due to its hepatotoxic side effects, oral ketoconazole was withdrawn from the European and Australian markets in 2013. The United States imposed strict relabeling requirements and restrictions for prescription, with Canada issuing a risk communication echoing these concerns. Today, oral ketoconazole is only indicated for endemic mycoses, where alternatives are not available or feasible. Meanwhile, topical ketoconazole is effective, safe, and widely prescribed for superficial mycoses, particularly as the first-line treatment for tinea versicolor.


Sign in / Sign up

Export Citation Format

Share Document